Post Content
Dyne Therapeutics (NASDAQ:DYN) is one of the most promising mid-cap healthcare stocks under $50.
As of the December 19 closing, the consensus analyst sentiment towards Dyne Therapeutics (NASDAQ:DYN) remains bullish. After a decline of almost 16% during 2025, the stock has received coverage from 10 analysts. 80% of them assigned Buy ratings, and the remaining 20% gave Hold calls. Such bullish forecasts have led to an estimated 1-year average price target of $38.40 per share, implying more than 93% upside for investors.
Romaset/Shutterstock.com
On December 15, Evercore ISI analyst Gavin Clark-Gartner reaffirmed his bullish stance on Dyne Therapeutics (NASDAQ:DYN). He assigned a Buy rating to the stock with a target price of $36. This implies a substantial upside potential of more than 81% for investors, compared with the stock’s current trading level.
Clark-Gartner’s Buy rating on Dyne Therapeutics (NASDAQ:DYN) stock is based on the company’s encouraging trends in functionality. He also highlighted how certain metrics on efficacy and safety remain in line with expectations. He sees these factors as a favorable catalyst for the stock after the company recently carried out a fundraising round.
Dyne Therapeutics (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. Dyne Therapeutics (NASDAQ:DYN) makes use of its FORCE platform to identify the root cause of a condition, and currently has a strong pipeline of clinical and preclinical programs.
While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.
Disclosure: None. This article is originally published at Insider Monkey.